Display options
Cite
Lafont V, Sanchez F, Laprevotte E, et al. Plasticity of γδ T Cells: Impact on the Anti-Tumor Response. Front Immunol. 2014;5:622doi: 10.3389/fimmu.2014.00622.
Lafont, V., Sanchez, F., Laprevotte, E., Michaud, H. A., Gros, L., Eliaou, J. F., & Bonnefoy, N. (2014). Plasticity of γδ T Cells: Impact on the Anti-Tumor Response. Frontiers in immunology, 5622. https://doi.org/10.3389/fimmu.2014.00622
Lafont, Virginie, et al. "Plasticity of γδ T Cells: Impact on the Anti-Tumor Response." Frontiers in immunology vol. 5 (2014): 622. doi: https://doi.org/10.3389/fimmu.2014.00622
Lafont V, Sanchez F, Laprevotte E, Michaud HA, Gros L, Eliaou JF, Bonnefoy N. Plasticity of γδ T Cells: Impact on the Anti-Tumor Response. Front Immunol. 2014 Dec 08;5:622. doi: 10.3389/fimmu.2014.00622. eCollection 2014. PMID: 25538706; PMCID: PMC4259167.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2014 Dec 08;5:622. doi: 10.3389/fimmu.2014.00622. eCollection 2014.

Plasticity of γδ T Cells: Impact on the Anti-Tumor Response.

Frontiers in immunology

Virginie Lafont, Françoise Sanchez, Emilie Laprevotte, Henri-Alexandre Michaud, Laurent Gros, Jean-François Eliaou, Nathalie Bonnefoy

Affiliations

  1. U896, Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM , Montpellier , France ; Centre Régional de Lutte Contre le Cancer CRLC Val d'Aurelle - Paul Lamarque, Université Montpellier 1 , Montpellier , France.
  2. U896, Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM , Montpellier , France ; Centre Régional de Lutte Contre le Cancer CRLC Val d'Aurelle - Paul Lamarque, Université Montpellier 1 , Montpellier , France ; Département d'Immunologie, Centre Hospitalier Régional Universitaire de Montpellier et Faculté de Médecine, Université Montpellier 1 , Montpellier , France.

PMID: 25538706 PMCID: PMC4259167 DOI: 10.3389/fimmu.2014.00622

Abstract

The tumor immune microenvironment contributes to tumor initiation, progression, and response to therapy. Among the immune cell subsets that play a role in the tumor microenvironment, innate-like T cells that express T cell receptors composed of γ and δ chains (γδ T cells) are of particular interest. γδ T cells can contribute to the immune response against many tumor types (lymphoma, myeloma, melanoma, breast, colon, lung, ovary, and prostate cancer) directly through their cytotoxic activity and indirectly by stimulating or regulating the biological functions of other cell types required for the initiation and establishment of the anti-tumor immune response, such as dendritic cells and cytotoxic CD8+ T cells. However, the notion that tumor-infiltrating γδ T cells are a good prognostic marker in cancer was recently challenged by studies showing that the presence of these cells in the tumor microenvironment was associated with poor prognosis in both breast and colon cancer. These findings suggest that γδ T cells may also display pro-tumor activities. Indeed, breast tumor-infiltrating γδ T cells could exert an immunosuppressive activity by negatively regulating dendritic cell maturation. Furthermore, recent studies demonstrated that signals from the microenvironment, particularly cytokines, can confer some plasticity to γδ T cells and promote their differentiation into γδ T cells with regulatory functions. This review focuses on the current knowledge on the functional plasticity of γδ T cells and its effect on their anti-tumor activities. It also discusses the putative mechanisms underlying γδ T cell expansion, differentiation, and recruitment in the tumor microenvironment.

Keywords: anti-tumor response; cytokines; plasticity; pro-tumor response; γδ T cells

References

  1. Immunol Rev. 2007 Feb;215:123-35 - PubMed
  2. Blood. 2004 Mar 15;103(6):2205-13 - PubMed
  3. Blood. 2009 Jul 9;114(2):310-7 - PubMed
  4. Mediators Inflamm. 2010;2010:704941 - PubMed
  5. J Invest Dermatol. 2001 Feb;116(2):275-80 - PubMed
  6. J Exp Med. 2003 Aug 4;198(3):433-42 - PubMed
  7. Cancer Res. 2007 Aug 1;67(15):7450-7 - PubMed
  8. Blood. 2012 Sep 13;120(11):2269-79 - PubMed
  9. Med Sci (Paris). 2010 Feb;26(2):185-91 - PubMed
  10. Cancer Immun. 2010 Nov 12;10:10 - PubMed
  11. J Exp Med. 1989 Nov 1;170(5):1569-81 - PubMed
  12. J Immunol. 2005 Aug 15;175(4):2144-51 - PubMed
  13. Cancer Metastasis Rev. 2012 Dec;31(3-4):553-68 - PubMed
  14. J Exp Med. 2003 Aug 4;198(3):391-7 - PubMed
  15. Immunity. 2007 Aug;27(2):334-48 - PubMed
  16. Trends Cell Biol. 2000 Dec;10(12):542-50 - PubMed
  17. J Exp Med. 2011 Mar 14;208(3):491-503 - PubMed
  18. J Immunol. 2013 Mar 1;190(5):2403-14 - PubMed
  19. Int J Cancer. 2008 Jun 1;122(11):2526-34 - PubMed
  20. Cancer Res. 2004 Dec 15;64(24):9172-9 - PubMed
  21. Immunity. 2008 Jul 18;29(1):90-100 - PubMed
  22. J Immunol. 2007 Apr 1;178(7):4304-14 - PubMed
  23. Cytokine. 2013 Nov;64(2):477-85 - PubMed
  24. Leuk Lymphoma. 2005 May;46(5):671-80 - PubMed
  25. Immunity. 2009 Aug 21;31(2):331-41 - PubMed
  26. J Immunol. 1999 Jul 1;163(1):242-9 - PubMed
  27. Eur J Immunol. 2009 May;39(5):1361-8 - PubMed
  28. Cell Mol Life Sci. 2011 Jul;68(14):2371-90 - PubMed
  29. J Immunol. 2002 Aug 1;169(3):1236-40 - PubMed
  30. J Immunol. 1997 Aug 1;159(3):1328-35 - PubMed
  31. Eur J Immunol. 1991 Dec;21(12):2999-3007 - PubMed
  32. Clin Cancer Res. 2008 Jul 1;14(13):4232-40 - PubMed
  33. Trends Immunol. 2011 Dec;32(12):567-73 - PubMed
  34. Immunol Lett. 2005 Jun 15;99(1):103-8 - PubMed
  35. J Exp Med. 1989 Apr 1;169(4):1277-94 - PubMed
  36. Immunity. 2005 Jan;22(1):71-80 - PubMed
  37. Cancer Immun. 2006 Mar 22;6:6 - PubMed
  38. Res Immunol. 1996 Jun;147(5):347-53 - PubMed
  39. J Immunother. 2008 Apr;31(3):313-23 - PubMed
  40. J Exp Med. 2009 Apr 13;206(4):743-50 - PubMed
  41. Immunol Lett. 2009 Dec 2;127(1):8-12 - PubMed
  42. Blood. 2011 Jul 7;118(1):129-38 - PubMed
  43. Cancer Immun. 2009 Nov 02;9:10 - PubMed
  44. Cell. 2011 Mar 4;144(5):646-74 - PubMed
  45. J Immunol. 2011 Jul 15;187(2):1031-8 - PubMed
  46. J Biol Chem. 2007 Jun 29;282(26):18922-8 - PubMed
  47. Cancer Immunol Res. 2014 Aug;2(8):732-40 - PubMed
  48. Immunol Today. 1996 Mar;17(3):138-46 - PubMed
  49. Clin Immunol. 2008 Aug;128(2):219-27 - PubMed
  50. Cell Immunol. 1999 May 25;194(1):12-20 - PubMed
  51. Cancer Immunol Immunother. 2008 Apr;57(4):531-9 - PubMed
  52. Leukemia. 2013 Jul;27(7):1580-5 - PubMed
  53. Biochem Biophys Res Commun. 2007 Mar 9;354(2):613-8 - PubMed
  54. Eur J Immunol. 2012 Jul;42(7):1668-76 - PubMed
  55. Immunology. 2009 Dec;128(4):580-8 - PubMed
  56. J Immunol. 2006 Feb 1;176(3):1386-93 - PubMed
  57. J Immunol. 1998 Oct 15;161(8):4138-45 - PubMed
  58. Eur J Immunol. 2009 Mar;39(3):662-6 - PubMed
  59. J Immunol. 2009 Mar 15;182(6):3423-31 - PubMed
  60. Cancer Biol Ther. 2009 Aug;8(16):1540-9 - PubMed
  61. Sci Rep. 2013 Dec 09;3:3456 - PubMed
  62. J Immunol. 2001 Jun 15;166(12):7190-9 - PubMed
  63. Cell Mol Life Sci. 2011 Jul;68(14):2399-408 - PubMed
  64. J Exp Med. 1990 May 1;171(5):1597-612 - PubMed
  65. J Immunol. 2009 Sep 15;183(6):3625-33 - PubMed
  66. Eur J Immunol. 2009 Jul;39(7):1794-806 - PubMed
  67. Nat Immunol. 2012 Sep;13(9):872-9 - PubMed
  68. Cancer Res. 2010 Dec 15;70(24):10024-7 - PubMed
  69. Cancer Immunol Immunother. 2007 Aug;56(8):1285-97 - PubMed
  70. J Immunol. 2005 Oct 15;175(8):5481-8 - PubMed
  71. Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17549-54 - PubMed
  72. J Immunol. 2011 Nov 15;187(10):4979-86 - PubMed
  73. Cancer Immunol Immunother. 2010 Jul;59(7):1109-20 - PubMed
  74. Exp Hematol. 2009 Jul;37(7):838-48 - PubMed
  75. Tumori. 2008 May-Jun;94(3):384-8 - PubMed
  76. J Immunol. 2010 Jun 15;184(12):7268-80 - PubMed
  77. Blood. 2003 Jul 1;102(1):200-6 - PubMed
  78. Science. 2005 Jul 8;309(5732):264-8 - PubMed
  79. Blood. 2010 Sep 9;116(10):1726-33 - PubMed
  80. Cancer Immunol Immunother. 2010 Jul;59(7):979-87 - PubMed
  81. J Immunol. 2010 Jun 15;184(12):6920-8 - PubMed
  82. J Immunol. 2009 Sep 15;183(6):3574-7 - PubMed
  83. Immunity. 1995 Oct;3(4):495-507 - PubMed
  84. Immunity. 2001 Jul;15(1):83-93 - PubMed
  85. Cell Immunol. 2001 Sep 15;212(2):110-7 - PubMed
  86. Int Immunol. 1997 Aug;9(8):1065-72 - PubMed
  87. J Clin Oncol. 2005 Apr 1;23(10):2346-57 - PubMed
  88. Immunity. 2014 Apr 17;40(4):490-500 - PubMed
  89. J Exp Med. 2003 Jan 20;197(2):163-8 - PubMed
  90. Cell Mol Immunol. 2013 Jan;10(1):13-20 - PubMed
  91. Trends Immunol. 2012 May;33(5):199-206 - PubMed
  92. Blood. 2004 Sep 15;104(6):1801-7 - PubMed
  93. J Immunol. 2005 Jan 1;174(1):252-60 - PubMed
  94. Blood. 2008 Jul 15;112(2):362-73 - PubMed
  95. J Exp Med. 2005 May 16;201(10):1567-78 - PubMed
  96. J Immunol. 2009 Nov 15;183(10):6413-21 - PubMed
  97. Immunity. 2011 Jul 22;35(1):59-68 - PubMed
  98. Oncogene. 2010 Oct 21;29(42):5653-62 - PubMed
  99. J Immunol. 2012 Feb 15;188(4):1708-16 - PubMed
  100. Blood. 2007 Aug 1;110(3):921-7 - PubMed
  101. Nat Immunol. 2009 Apr;10(4):427-36 - PubMed
  102. J Immunol. 2012 Nov 15;189(10):5029-36 - PubMed
  103. J Immunol. 2010 Jul 1;185(1):126-33 - PubMed
  104. Blood. 2010 Mar 25;115(12):2407-11 - PubMed
  105. J Immunol. 2012 Apr 15;188(8):3928-39 - PubMed
  106. Nature. 2002 Oct 17;419(6908):734-8 - PubMed
  107. Annu Rev Immunol. 1992;10:385-409 - PubMed
  108. J Immunol. 2011 Jun 1;186(11):6091-5 - PubMed
  109. Eur J Immunol. 2012 Jan;42(1):110-9 - PubMed
  110. J Biol Regul Homeost Agents. 2014 Jan-Mar;28(1):81-90 - PubMed
  111. Cancer Res. 2009 Nov 15;69(22):8710-7 - PubMed
  112. FEBS Lett. 2001 Dec 7;509(2):317-22 - PubMed
  113. Haematologica. 2011 Mar;96(3):400-7 - PubMed
  114. Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6879-84 - PubMed
  115. PLoS One. 2012;7(11):e49878 - PubMed
  116. Clin Exp Immunol. 2010 Aug;161(2):290-7 - PubMed
  117. Cytotherapy. 2012 Oct;14(9):1110-8 - PubMed
  118. Nature. 1990 Feb 22;343(6260):754-7 - PubMed
  119. Immunity. 2011 Oct 28;35(4):596-610 - PubMed
  120. Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2307-12 - PubMed
  121. Scand J Immunol. 2007 Aug-Sep;66(2-3):320-8 - PubMed
  122. Blood. 2000 Jul 15;96(2):384-92 - PubMed
  123. J Immunol. 2001 Mar 15;166(6):3655-8 - PubMed
  124. Curr Opin Immunol. 2006 Oct;18(5):539-46 - PubMed
  125. Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2414-9 - PubMed
  126. J Immunol. 2014 Mar 1;192(5):2237-43 - PubMed
  127. Histopathology. 2013 Aug;63(2):225-33 - PubMed
  128. Int Arch Allergy Immunol. 1992;98(4):279-85 - PubMed
  129. Blood. 2009 May 14;113(20):4875-84 - PubMed
  130. Clin Cancer Res. 2014 Nov 15;20(22):5708-19 - PubMed
  131. Nat Rev Immunol. 2010 Jul;10(7):467-78 - PubMed
  132. PLoS One. 2013;8(1):e51805 - PubMed
  133. Immunity. 2014 May 15;40(5):785-800 - PubMed
  134. PLoS One. 2012;7(7):e41940 - PubMed
  135. J Immunol. 2009 Oct 1;183(7):4169-75 - PubMed
  136. Nat Immunol. 2013 Oct;14(10):1093-100 - PubMed
  137. Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):E3562-70 - PubMed
  138. Annu Rev Immunol. 2000;18:975-1026 - PubMed
  139. Science. 1998 Mar 13;279(5357):1737-40 - PubMed
  140. J Immunol. 2010 Mar 15;184(6):3260-8 - PubMed
  141. Drugs Exp Clin Res. 1987;13(6):327-37 - PubMed

Publication Types